CRL vs INTS
Charles River Laboratories (CRL) versus Intensity Therapeutics, Inc. Common stock (INTS) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Latest reported CRL revenue for 2024-12-28 was $4.05B. Net income was $25.3M. Revenue was down 1.9% from 2023-12-30 to 2024-12-28. CRL currently screens at market cap $7.78B.
INTS does not have a complete income-statement cache yet.
CRL currently screens at market cap $7.78B. INTS currently screens at market cap $7.7M.
Not investment advice. Open the CRL and INTS stock pages for the full models.
Not investment advice.